Hospitalizations expressed per patient for all patients and for patients actually hospitalized during the trial
| . | Ivabradine (n = 3241) . | Placebo (n = 3264) . | P-value . |
|---|---|---|---|
| Hospitalizations for worsening heart failure (number of patients) | |||
| No hospitalization | 2727 (84%) | 2592 (79%) | |
| 1 hospitalization | 325 (10%) | 389 (12%) | |
| 2 hospitalizations | 99 (3%) | 155 (5%) | |
| ≥3 hospitalizations | 90 (3%) | 128 (4%) | |
| Hospitalizations for worsening heart failure (number of events) | |||
| Total number of hospitalization events | 902 | 1211 | 0.0002 |
| Number of events per patient | |||
| Whole population | 0.3 | 0.4 | |
| Patients with ≥1 hospitalization | 1.8 | 1.8 | |
| Hospitalizations for any cause (number of patients) | |||
| No hospitalization | 2010 (62%) | 1908 (58%) | |
| 1 hospitalization | 613 (19%) | 646 (20%) | |
| 2 hospitalizations | 297 (9%) | 313 (10%) | |
| ≥3 hospitalizations | 321 (10%) | 397 (12%) | |
| Hospitalizations for any cause (number of events) | |||
| Total number of hospitalization events | 2661 | 3110 | 0.001 |
| Number of events per patient | |||
| Whole population | 0.8 | 1.0 | |
| Patients with ≥1 hospitalization | 2.2 | 2.3 | |
| . | Ivabradine (n = 3241) . | Placebo (n = 3264) . | P-value . |
|---|---|---|---|
| Hospitalizations for worsening heart failure (number of patients) | |||
| No hospitalization | 2727 (84%) | 2592 (79%) | |
| 1 hospitalization | 325 (10%) | 389 (12%) | |
| 2 hospitalizations | 99 (3%) | 155 (5%) | |
| ≥3 hospitalizations | 90 (3%) | 128 (4%) | |
| Hospitalizations for worsening heart failure (number of events) | |||
| Total number of hospitalization events | 902 | 1211 | 0.0002 |
| Number of events per patient | |||
| Whole population | 0.3 | 0.4 | |
| Patients with ≥1 hospitalization | 1.8 | 1.8 | |
| Hospitalizations for any cause (number of patients) | |||
| No hospitalization | 2010 (62%) | 1908 (58%) | |
| 1 hospitalization | 613 (19%) | 646 (20%) | |
| 2 hospitalizations | 297 (9%) | 313 (10%) | |
| ≥3 hospitalizations | 321 (10%) | 397 (12%) | |
| Hospitalizations for any cause (number of events) | |||
| Total number of hospitalization events | 2661 | 3110 | 0.001 |
| Number of events per patient | |||
| Whole population | 0.8 | 1.0 | |
| Patients with ≥1 hospitalization | 2.2 | 2.3 | |
P-values comparing patients in the ivabradine and placebo groups (Poisson's regression model).
Hospitalizations expressed per patient for all patients and for patients actually hospitalized during the trial
| . | Ivabradine (n = 3241) . | Placebo (n = 3264) . | P-value . |
|---|---|---|---|
| Hospitalizations for worsening heart failure (number of patients) | |||
| No hospitalization | 2727 (84%) | 2592 (79%) | |
| 1 hospitalization | 325 (10%) | 389 (12%) | |
| 2 hospitalizations | 99 (3%) | 155 (5%) | |
| ≥3 hospitalizations | 90 (3%) | 128 (4%) | |
| Hospitalizations for worsening heart failure (number of events) | |||
| Total number of hospitalization events | 902 | 1211 | 0.0002 |
| Number of events per patient | |||
| Whole population | 0.3 | 0.4 | |
| Patients with ≥1 hospitalization | 1.8 | 1.8 | |
| Hospitalizations for any cause (number of patients) | |||
| No hospitalization | 2010 (62%) | 1908 (58%) | |
| 1 hospitalization | 613 (19%) | 646 (20%) | |
| 2 hospitalizations | 297 (9%) | 313 (10%) | |
| ≥3 hospitalizations | 321 (10%) | 397 (12%) | |
| Hospitalizations for any cause (number of events) | |||
| Total number of hospitalization events | 2661 | 3110 | 0.001 |
| Number of events per patient | |||
| Whole population | 0.8 | 1.0 | |
| Patients with ≥1 hospitalization | 2.2 | 2.3 | |
| . | Ivabradine (n = 3241) . | Placebo (n = 3264) . | P-value . |
|---|---|---|---|
| Hospitalizations for worsening heart failure (number of patients) | |||
| No hospitalization | 2727 (84%) | 2592 (79%) | |
| 1 hospitalization | 325 (10%) | 389 (12%) | |
| 2 hospitalizations | 99 (3%) | 155 (5%) | |
| ≥3 hospitalizations | 90 (3%) | 128 (4%) | |
| Hospitalizations for worsening heart failure (number of events) | |||
| Total number of hospitalization events | 902 | 1211 | 0.0002 |
| Number of events per patient | |||
| Whole population | 0.3 | 0.4 | |
| Patients with ≥1 hospitalization | 1.8 | 1.8 | |
| Hospitalizations for any cause (number of patients) | |||
| No hospitalization | 2010 (62%) | 1908 (58%) | |
| 1 hospitalization | 613 (19%) | 646 (20%) | |
| 2 hospitalizations | 297 (9%) | 313 (10%) | |
| ≥3 hospitalizations | 321 (10%) | 397 (12%) | |
| Hospitalizations for any cause (number of events) | |||
| Total number of hospitalization events | 2661 | 3110 | 0.001 |
| Number of events per patient | |||
| Whole population | 0.8 | 1.0 | |
| Patients with ≥1 hospitalization | 2.2 | 2.3 | |
P-values comparing patients in the ivabradine and placebo groups (Poisson's regression model).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
